Dechra Pharmaceuticals PLC Annual Report and Accounts for the year ended 30 June 2021

Our Purpose
and Strategy

Our Purpose

What we do

The sustainable improvement of animal health and welfare globally

Our Purpose

Why we exist

The sustainable improvement of animal health and welfare globally

Our Approach to ESG

Our ESG strategy is based on our Purpose and Values

We have chosen to support the United Nations Sustainable Development Goals (SDGs).

Our Strategy

How we achieve our purpose

Strategic Growth Drivers

Pipeline
Delivery

Portfolio
Focus

Geographical
Expansion

Acquisition

Strategic Enablers

Manufacturing &
Supply Chain

Technology

People

ESG

See our Strategic Drivers Case Studies

Our Values

Fundamental beliefs that underpin everything we do

Dedication

icon

Enjoyment

icon

Courage

icon

Honesty

icon

Relationships

icon

Ambition

icon

Our Culture

Ethical foundation enabling better decisions every day

Our Values, entrepreneurial attitude and agile approach to the way we do things are the backbone of our Culture.

We expect our people to make a difference by collaborating with each other and we support them by providing clear guidance on expectations.

Our Products

Our products can be divided into four categories, as set out below. All are targeted at providing veterinary professionals with solutions for their customers’ needs.

Companion Animal Products (CAP)

Species: Dogs and cats

Key therapeutic sectors: Endocrinology, dermatology, analgesia and anaesthesia, antiobiotics, cardiovascular and critical care.

72.8% of Group Revenue

Food producing Animal Products (FAP)

Species: Poultry, pigs and an increasing presence in cattle.

Key therapeutic sectors: Water soluble antibiotics, poultry vaccines, locomotion (lameness) and pain management.

12.7% of Group Revenue

Equine

Species: Horses and ponies

Key therapeutic sectors: Locomotion (lameness) and pain management.

7.3% of Group Revenue

Nutrition

Species: Dogs and cats.

Key therapeutic sectors: Our pet diets are available to support the wellbeing of animals with numerous therapeutic conditions.

5.2% of Group Revenue

Our Product Pipeline

A key strategic priority for the Group is the delivery and strength of the pipeline. We currently have 33 projects in the product development process:

Our Global Footprint

We currently have sales and marketing organisations in 25 countries and market our products in 68 other countries worldwide through distributors or marketing partners.

Manufacturing Sites

Logistics Sites

Sales and Marketing

Distribution Partners